

INDEX
TUBERCULOSIS
CLINICAL POLICIES AND PROCEDURES, 4TH EDITION MARCH 2008

Acid-fast bacilli smears

Centers for Disease Control and Prevention tuberculosis-classified immigrants, 231
in children, 37
in contact evaluation, 155, 156, 158, 159, 160, 202
conversion, 102, 154
at end of intensive phase of treatment, 102, 103
in examination of the placenta, 38
for infection control, 121, 122, 124, 130
in initial evaluation, 27, 29
in multidrug-resistant tuberculosis, 201, 202
pertaining to regulatory interventions, 103, 147
in pregnant women, 130
quantitation scale, 30
reporting requirements, 229, 230
with rifapentine use, 12, 46, 47
during and after treatment, 101, 103, 115, 116
at end of treatment, 102, 103

Acquired rifamycin resistance (ARR), 53

with intermittent regimens, 53
relapse due to, 117
with rifapentine, 13, 48, 49, 53

Adherence

to active tuberculosis treatment, 142
ensuring, 142
to HAART regimens, 49
incentives for, 63, 142, 203
to latent tuberculosis infection treatment, 195, 201, 203
monitoring, 105, 116, 127, 139
prioritization for locating non-adherent patients, 144
referral for detention, 145
standards, 236, 237

Adverse events – see *Adverse reactions*

Adverse reactions, 101, 105, 203, 208, 210

audiotoxicity – see *Audiovestibular manifestations*
audiovestibular manifestations, 105, 112
blood sugar abnormalities – see *Hypoglycemia/hyperglycemia*
cardiotoxicity, 92, 93
in children, 60
in clinically confirmed patients, 202
dermatitis, 105, 106, 208, 210
drug desensitization, 113
gastritis, 105, 110, 208, 210

- grades of toxicity, 114
- hematologic manifestations, 94, 105, 111, 208, 210
- hepatitis, 92, 104, 105, 107, 208, 210
- in HIV–infected patients, 49, 56
- hypoglycemia/hyperglycemia, 13, 91, 93, 105, 210
- hypothyroidism, 104, 105, 210
- joint manifestations, 105, 111, 208, 210
- lactic acidosis, 94
- in latent tuberculosis infection patients, 195
- management of adverse reactions, 106
- in multidrug-resistant tuberculosis patients, 84, 92
- medication orders, 104
- neurologic manifestations, 105, 210
- with non-nucleoside reverse transcriptase inhibitors, 50, 51
- with nucleoside/nucleotide reverse transcriptase inhibitors, 51
- paradoxical reactions, 56, 113
- peripheral neuropathy, 62, 94, 105, 110, 196, 208, 217, 220
- photosensitivity/phototoxicity, 92, 106, 210
- psychiatric manifestations, 105, 210
- in pregnant women, 193
- with primary tuberculosis medications, 208
 - rifapentine, 48
 - with protease inhibitors, 50
- renal manifestations, 105, 111, 208, 210
- reporting of, 114
- with reserve tuberculosis medications, 83, 210
 - fluoroquinolones, 85, 92, 93
- serotonin syndrome, 95
- tendinopathy/tenosynovitis, 92, 105, 210
- visual manifestations, 94, 105, 112, 208

AFB smears – see *Acid-fast bacilli smears*

Airborne infection isolation (AII), 37, 114, 122

- admission to, 121, 123
- discharge from, 102, 124
- influence of nucleic acid amplification results on, 125
- transfer to non-airborne infection isolation rooms, 124

Airline exposure, 167, 168

Alternative regimens for latent tuberculosis infection treatment, 195 – see *Latent tuberculosis infection treatment*

Amikacin – see *Aminoglycosides, Injectable anti-tuberculosis medications*

- adverse reactions to, 105, 111, 210
- breast feeding and, 211
- central nervous system penetration of, 74, 211
- cross-resistance to kanamycin, 83, 91
- dose and frequency of, 61, 85, 210
- drug interactions, 216
- indications for, 83, 85, 86
- in liver disease, 62, 211

with *Mycobacterium avium intracellulare*, 67
monitoring, 84, 210
in neonates, 38
in pregnancy, 58, 211
in renal failure, 61, 211
use in “W” strain, 91

Aminoglycosides – see *Injectable anti-TB medications, Amikacin, Kanamycin, Streptomycin*

Amplicor® – see *Nucleic acid amplification tests*

Anergy, 176, 182, 184, 192

Anergy testing, 182

Antiretroviral drugs – see *HIV infection, Protease inhibitors, Non-Nucleoside reverse transcriptase inhibitors, Nucleoside/Nucleotide reverse transcriptase inhibitors*

Anti-tuberculosis drugs and meals, 62

Associate investigation, 153, 162, 167, 169

Audiometry, 105, 208, 210

Audiovestibular manifestations, 105, 112, 208, 210

Bactericidal anti-tuberculosis medications, 84, 85, 208, 210

Bacteriostatic anti-tuberculosis medications, 208, 210

Bacille Calmette-Guerin (BCG) vaccine, 227

booster phenomenon, 182,
disease due to intravesicular use, 78
evaluation and follow up, 228
indications for use, 38, 164, 174, 227
for infants, 164, 228
tuberculin skin testing and, 179, 181

Biweekly therapy – see *Twice weekly therapy, Intermittent therapy*

Blood-based tests for tuberculosis infection, – see *QuantiFERON® TB Gold*

Blood sugar abnormalities – see *Hypoglycemia/Hyperglycemia*

Booster phenomenon, 182

Breastfeeding and anti-tuberculosis medications, 48, 58, 62, 196, 200, 209, 211

Capreomycin – see *Injectable anti-tuberculosis medications*

adverse reactions to, 105, 111, 210
breast feeding and, 211
central nervous system penetration of, 74, 211
dose and frequency of, 85, 210
drug interactions, 216
indications for, 83, 85, 86
in liver disease, 62, 211
monitoring, 84, 210, 215
in pregnancy, 58, 211
in renal failure, 61, 211

Cardiotoxicity, 92, 93, 217

Case closing, 115

Case management, 12, 139, 140

flow chart, 140
initial interview topics, 141

for treatment of contacts with latent tuberculosis infection, 169, 202

Cavitary tuberculosis disease

airborne infection isolation and, 122

in children, 37

in contact investigation, 155, 156, 158, 160, 161

increased risk of relapse and, 44, 46

infectiousness of, 122, 155, 160, 161, 198

upon initial evaluation, 13, 25, 36

late complications of treatment and, 212

length of treatment, 13, 43, 103

in multidrug-resistant tuberculosis patients, 83, 88, 90

and rifapentine, 46, 47

surveillance and, 103, 234

treatment completion and, 64

Central nervous system tuberculosis, 38, 56, 71, 73, 79, 113, 121, 123, 211, 227 – see *Meningeal tuberculosis, Tuberculoma*

Cerebrospinal fluid, 74

medication levels in, 211

in meningeal tuberculosis, 74

specimen collection, 27, 29

Chemistry panel, 36, 103, 104, 190, 208, 210

Chest pain, 73, 114, 190, 212

Chest X-ray

Centers for Disease Control and Infection tuberculosis-classified immigrants, 231

changes after treatment, 213

for children, 37, 164, 165

for Class IV, 115, 200

for evaluation of contacts, 162, 163, 164, 165

for evaluation of tuberculosis disease, 25, 35, 36, 72, 73, 75, 76, 78

for infection control, 122, 130

interrupted or incomplete treatment, 65

after latent tuberculosis infection treatment, 205

before latent tuberculosis infection treatment, 174, 179, 189, 192

lateral chest X-ray, 37

lead shield, 27, 190, 194

after multidrug-resistant tuberculosis treatment, 115, 116

for neonates, 38

for patients with previous positive tests for tuberculosis infection, 163

post-treatment evaluation, 101, 103, 115, 116

for pregnant women, 27, 130, 190, 194

reporting requirements, 230

for source case investigations, 167

during tuberculosis treatment, 13, 43, 67, 101, 103

at end of tuberculosis treatment, 14, 115

Children with tuberculosis

congenital and neonatal tuberculosis, 38

diagnosis of, 28, 37, 38

drug resistance and, 28, 38, 84

evaluation of, 26, 37
extrapulmonary disease, 37, 60, 71, 73, 75, 227
gastric aspirates in, 28
intermittent regimens, 59
source case investigations for, 167
treatment, 59, 60
 adverse reactions and, 60
 dosages of tuberculosis drugs, 210
 with ethambutol, 14, 59, 84, 208
 with fluoroquinolones, 84, 85, 92, 210
 length regardless of culture results, 60
 of meningitis, 74
 with rifapentine, 47, 48
 steroids for, 74, 79
 visual manifestations in, 14, 59

Chronic renal failure - see *Renal failure*

Ciprofloxacin — see *Fluoroquinolones*

Class IV (old, healed tuberculosis), 36, 63, 101, 115, 190, 200, 201, 202, 234, inside back cover
 evaluation for, 173, 174, 200
 treatment of, 13, 200

Class V (High) versus (Low), 36, 56, 63, 101, 114, 115, 127, 162, 190, 200, 232, 234, inside back cover

Classification of tuberculosis, 36, 114, 162, 163, 164, inside back cover

Clinical examination – see *Medical evaluation*

Clinically confirmed tuberculosis - see *Culture–negative tuberculosis*

Clofazimine, 58, 86, 91, 95

Clubbed fingers, 213

Cohort review, 140, 143, 169

Commissioner’s Orders - see *Regulatory interventions*

Complete blood count, 36, 48, 94, 103, 104, 112, 190, 196, 199, 209

Completion of treatment

 for latent tuberculosis infection, 195, 196, 202, 205

 for tuberculosis, 43, 45, 48, 57, 60, 64

 in children, 60

 for culture negative pulmonary tuberculosis, 44,

 for culture-positive pulmonary tuberculosis, 43, 45

 for extrapulmonary tuberculosis, 72, 73, 76, 77, 78, 79

 for multidrug resistant tuberculosis, 86, 87, 88, 89, 90, 91

 for pregnant women, 57

 with rifapentine, 47, 48

Confidentiality, 16, 20, 155, 238

Concentric circle, 153, 155, 157, 165

Congenital tuberculosis, 38, 122, 130, 190

Contact evaluation, 153 – see *Contacts, Contact investigation*

 airline exposure, 167, 168

 assessing risk of transmission, 161

 calculating the infectious period, 161

 and case management, 140, 141

- chest x-ray for, 162, 163, 164
- concentric circle, 155, 157, 167
- confidentiality, 18, 19, 155
- for culture-negative non-cavitary pulmonary tuberculosis 157, 159
- decision to conduct or continue, 156
- epidemiologic assessment of transmission, 155
- expanding, 165, 166
- for extrapulmonary tuberculosis, 157
- infant and child contacts, 28, 37, 71, 164, 177, 227
- medical evaluation, 163
- for patients whose cultures convert back to positive, 164
- for patients with negative Amplicor® or MTD®, 156
- priorities and prioritization of, 155, 158, 159, 160
- for smear-negative, culture-pending cases, 165
- source case investigation, 167
- tests for tuberculosis infection in, 162, 163, 164, 165, 167
- window period, 155, 162, 163, 164, 165, 166, 176
- window period treatment (prophylaxis), 38, 155, 193

Contact investigation – see *Contact evaluation*

Contacts – see also *Contact evaluation*

- to AFB smear-negative patients, 159
- to AFB smear-positive patients, 158
- blood-based test for tuberculosis infection for, 184
- case management of, 169
- chest X-ray for, 162, 163, 164
- classification of, 163
- close, 153, 154, 157, 160
- determination of positive skin test reaction for, 180
- directly observed therapy (DOT) for latent tuberculosis infection, 203
- high-priority contacts, 154, 155, 158, 159, 160
- HIV screening and testing of, 162
- infants and children who are, 28, 37, 71, 164, 177, 227
- initial test for tuberculosis infection in, 162, 164
- latent tuberculosis infection treatment for, 169, 189, 192, 193, 195
- management of, 161
- medical evaluation for, 163
- other-than-close, 153, 154, 157
- of patients with multidrug-resistant tuberculosis, 127, 198, 199, 200, 201, 205, 227
- who are pregnant, 194, 200
- with prior positive test for tuberculosis infection, 162, 163, 202
- repeat test for tuberculosis infection, 163, 165, 174
- reporting requirements for, 229, 230
- symptom review, 161
- test for tuberculosis infection of, 162, 163, 164, 173, 174, 176, 184, 227

Continuation phase of tuberculosis treatment, 43, 45, 48, 52, 58, 60, 86, 103, 236

- for culture-negative pulmonary tuberculosis, 44, 58
- for culture-positive pulmonary tuberculosis, 43, 45
- extension of treatment in, 13, 43, 46, 47

for extrapulmonary tuberculosis, 71, 74
intermittent therapy during, 44, 45, 53
interrupted treatment during, 65, 66
for multidrug-resistant tuberculosis, 86
with rifapentine, 12, 47, 48, 209

Conversion of skin test result, 154, 163, 166, 192, 193, 198, 200, 202, 205, 228

Converters – see *Conversion of skin test result*

Corticosteroids, 79

for congenital tuberculosis, 38
for disease due to intravesical Bacille Calmette-Guérin, 78
for disseminated tuberculosis, 76, 79
dosages, 56, 73, 74
with fluoroquinolones, 93, 217
for immune reconstitution inflammatory syndrome, 56
for meningeal tuberculosis, 74, 75, 79
for neonates, 38
for paradoxical reactions, non-HIV related, 113
for pericardial tuberculosis, 73, 79
for pleural tuberculosis, 73
for respiratory failure, 76, 79
with rifampin, 222
risk of developing tuberculosis due to, 160, 173, 174, 176, 192
for tuberculoma, 75, 79

CSF – see *Cerebrospinal fluid*

CT scans for tuberculosis diagnosis - 72, 96, 212

Culture

conversion, 12, 101, 102, 125, 127, 129, 130, 161, 214
in drug-resistant tuberculosis, 83, 85, 86, 96
false-positive, 35
frequency of collection of, 101, 103
mycobacterial, 31
reversion, 96, 154

Culture-negative tuberculosis

in children, 60
classification of, 114
post-treatment evaluation for, 115
in pregnant women, 58
treatment of, 13, 44, 58, 103

Culture-positive, pulmonary tuberculosis

for children, 59
post-treatment evaluation for, 115
in pregnant women, 57
treatment of, 43,

Culture-positive relapse, 46

Cutaneous tuberculosis, 77

Cycloserine

adverse reactions to, 105, 111, 210
breast feeding and, 211

- central nervous system penetration of, 211
- dose and frequency of, 210
- drug interactions, 217, 220
- eosinophilia with, 111
- indications for, 83, 86, 201
- in liver disease, 211
- monitoring, 210, 214
- in pregnancy, 211
- pyridoxine with, 62, 210
- in renal failure, 61, 211

CYP3A, 49, 50, 52

Dermatitis, 105, 106, 208, 210

Detention – see *Regulatory interventions*

Diagnosis

- of tuberculosis disease – see *Evaluation for tuberculosis disease*
- of tuberculosis infection – see *Blood-based tests for tuberculosis infection, Tuberculin skin test*

Dialysis and tuberculosis medications, 60, 211

Directly observed therapy (DOT), 12, 63, 101

- agreement for clinic DOT, 242
- agreement for field DOT, 240
- and intermittent therapy for latent tuberculosis infection, 196
- and intermittent therapy for tuberculosis, 44, 45, 104, 208
- for latent tuberculosis infection, 195, 203
- mandatory, 146, 147
- missed visits, 143
- protocol for, 63
- prioritization of patients for, 64
- rifapentine and, 46, 47
- for tuberculosis treatment, 12, 63, 101

Discharge

- from airborne infection isolation, 123, 124, 125, 126
- from the hospital, 14, 102, 125, 128
 - of an acid fast bacilli smear-negative patient, 126
 - of a patient with suspected/confirmed multidrug-resistant tuberculosis, 126
 - while still potentially infectious, 124, 128, 244

Disease due to intravesical Bacille Calmette-Guérin for bladder cancer, 78

Disseminated tuberculosis, 29, 37, 56, 72, 75, 79, 106, 107, 113, 121 – see *Miliary tuberculosis*

DOPT (directly observed preventive therapy) – see *Directly observed therapy for latent tuberculosis infection*

Dosages for treatment

- for latent tuberculosis infection, 196
- for tuberculosis, 45, 208, 210

DOT – see *directly observed therapy*

Drug concentrations – see *drug susceptibility testing*

Drug desensitization, 113

Drug interactions

with antiretroviral medications, 49, 208
with anti-tuberculosis medications, 216
with rifapentine, 16, 48, 55

Drug susceptibility testing, 32

drug concentrations for, 33
interpretation of, 32
methods of, 32

Drug-resistant tuberculosis – see *Multidrug-resistant tuberculosis, Isoniazid-resistant tuberculosis, Rifampin-resistant tuberculosis*

risk factors for, 26
treatment of, 83, 86

Duration of treatment – see *Length of treatment***Dyspnea, 73, 213****Electrolytes, 36, 111, 208, 210****Electronic cap monitoring, 142****Electronic Clinical Laboratory Reporting System (ECLRS), 230****Electronic Disease Notification (EDN), 231****Eosinophilia, 105, 111, 210** – see *Capreomycin, adverse reaction to***Epidemiology, 16, 35, 155****Ethambutol**

adverse reactions to, 105, 208
breast feeding and, 211
central nervous system penetration of, 211
in children, 14, 59, 208
discontinuation of, 43, 44, 57, 59, 103
dose and frequency of, 45, 196, 208
drug levels for, 61, 214
indications for, 45, 86, 201
in liver disease, 61, 211
monitoring, 61, 208
monitoring vision, 27, 59, 103, 208
in pregnancy, 14, 57, 211
in renal failure, 60, 211
resistance, 86, 87, 89,
for treatment of Class IV, 200
for treatment of multidrug-resistant tuberculosis, 84, 85, 86, 89, 90, 91
for treatment of multidrug-resistant tuberculosis contacts, 201

Ethionamide

adverse reactions to, 105, 210
breast feeding and, 211
central nervous system penetration of, 74, 211
dose and frequency of, 210
drug interaction, 210, 217, 220
indications for, 84, 86, 89, 90, 91
in liver disease, 61, 104, 211
monitoring, 104, 210

- in pregnancy, 58, 211
- in renal failure, 60, 211
- resistance, 86, 90
- and thyroid function testing, 104, 210
- for treatment of multidrug-resistant tuberculosis contacts, 201

Evaluation for tuberculosis disease, 25

- bacteriology, 27
- in children, 37
- Class V (high) versus (low), 36
- for culture-negative tuberculosis, 44
- drug susceptibility testing, 32
- extrapulmonary tuberculosis, 71, 72
- genotyping, 34
- HIV testing, 26, 36
- laboratory tests, 36
- microbiologic, 27
- nucleic acid amplification, 30
- physical examination, 26
- radiographic, 27
- tests for tuberculosis infection, 26

Extrapulmonary tuberculosis, 71 – see *Individual sites*

- chest X-ray and, 27
- in children, 37, 60
- congenital tuberculosis, 38
- corticosteroids for, 38, 73, 74, 75, 76, 79
- evaluation by specific site, 72
 - central nervous system tuberculosis, 73
 - cutaneous tuberculosis, 77, 78
 - disease due to intravesical BCG for bladder cancer, 78
 - disseminated tuberculosis, 75
 - gastrointestinal tuberculosis, 77
 - genitourinary tuberculosis, 76
 - lymphatic tuberculosis, 72
 - pericardial tuberculosis, 73
 - peritoneal tuberculosis, 77
 - pleural tuberculosis, 72
 - skeletal tuberculosis, 76
- length of treatment, 71, 79
- nucleic acid amplification tests for, 30, 31
- paradoxical reactions, non-HIV related, 113
- treatment of, 71 – see *Individual sites*

Expanding contact investigation, 165, 166

Extreme drug-resistance, 86

Failure – see *Treatment failure*

False-positive results, 35, 36, 181

- due to BCG, 175, 181, 182
- investigations, 35

in tuberculin skin testing, 173

False-negative results, 176, 179, 181, 193

Fluoroquinolones – see also *Gatifloxacin*, *Levofloxacin*, *Moxifloxacin*

adverse reactions to, 85, 92, 105, 210

breastfeeding and, 211

central nervous system penetration of, 211

in children, 84, 85, 92, 210

dose and frequency of, 210

drug interactions, 217

indications for, 13, 85, 86, 91

in liver disease, 13, 62, 211

with *Mycobacterium avium intracellulare*, 67

monitoring, 93, 210

in pregnancy, 85, 211

in renal insufficiency, 61, 211

for treatment of drug-resistant tuberculosis, 85, 86, 87

for treatment of multidrug-resistant tuberculosis, 86, 87, 88, 89, 90, 91

for treatment of multidrug-resistant tuberculosis contacts, 92, 201

Follow-up – see *Monitoring*

Gastric aspiration, 28

Gastritis, 95, 105, 110, 208, 210

Gastrointestinal tuberculosis, 77

Gatifloxacin, 91, 93, 218 – see also *Fluoroquinolones*

Genitourinary tuberculosis, 71, 76, 79

Genotyping, 34

Gen-Probe – see *Nucleic acid amplification tests*

Gout – see *Joint manifestations*

Guidelines

Bureau of Tuberculosis Control vs. American Thoracic Society, Centers for Disease

Control and Infection, Infectious Disease Society of America, 13

Hospitalization and discharge, 14, 121

Health Code tuberculosis related sections, 16, 63, 145, 155, 177, 229

Health Systems Examination, 234

Hearing loss – see *Audiovestibular manifestations*

Hematologic manifestations, 94, 105, 111, 208, 210

Hemodialysis, 60, 211

Hemoptysis, 96, 121, 212

Hepatitis, 48, 92, 104, 105, 107, 208, 210, 211

liver sparing regimen, 61

latent tuberculosis infection treatment, 189, 190, 191, 195, 196, 198, 199, 200, 203, 204, 208, 219

management of drug-induced, 109

non-drug related, 110

due to rifampin and pyrazinamide, 15, 198

screening, 36, 60, 103, 109

viral, 36, 61, 104, 107, 109

High efficiency particulate air (HEPA) filter, 28, 129, 134

High tuberculosis-incidence areas of the world, 175

Highly Active Antiretroviral Therapy (HAART) – see *HIV-infection, Protease inhibitors, Non-nucleoside reverse transcriptase inhibitors, and Nucleoside/nucleotide reverse transcriptase inhibitors*

HIPAA (Health Insurance Portability and Accountability Act of 1966) – see *Confidentiality*

HIV infection

- antiretroviral drugs and rifabutin, 14, 49, 54, 55, 195, 197
- antiretroviral drugs and rifampin, 14, 49, 54, 55, 195, 196
- Bacille Calmette Guérin vaccination, 227
- confidentiality, 17
- epidemiology, 16
- latent tuberculosis infection and,
 - anergy testing, 182
 - classification of tuberculin skin test, 180
 - HIV-infected contacts, 157, 158, 159, 160, 163, 174, 176, 190, 191
 - treatment in, 163, 164, 189, 195, 197, 203
- tuberculosis and, 49
 - diagnosis, 26
 - DOT, 13, 63
 - drug interactions, 14, 49, 54, 55
 - drug-resistant tuberculosis, 83, 84
 - extrapulmonary disease, 71
 - general considerations, 52
 - immune reconstitution inflammatory syndrome (IRIS), 56
 - intermittent regimens, 13, 44, 45, 53, 54
 - interrupted or incomplete treatment, 65, 66
 - length of treatment, 53
 - monitoring, 103, 104
 - post-tuberculosis treatment evaluation, 117
 - in pregnant women, 53, 57, 194
 - pyridoxine and, 62
 - rifapentine in, 13, 44, 46, 47
 - treatment options, 52, 54
 - women of childbearing age, 53
 - testing for cases and contacts, 26, 36, 162, 189

Holding regimen, 67, 84

Home isolation, 124, 126, 127, 129

- agreement, 129, 246

Homeless patients, 64, 142, 156, 165, 174, 180

Hospitalization for tuberculosis, 14, 121, 122, 123

Host immune response, 25

Hypoglycemia/hyperglycemia, 13, 93, 210

Hypothyroidism, 104, 105, 210

Immigrants, 15, 20, 173, 174, 176, 231, 234

Immune reconstitution inflammatory syndrome (IRIS), 52, 56, 75

Incentives for patients, 63, 142, 203

Incomplete treatment – see *Interrupted treatment*

Index case, 154, 157

Infants – see *Pediatric tuberculosis*

Infection control, 121

airborne infection isolation, 102, 114, 121, 122, 123, 124, 125

in chest centers, 131

temporary isolation, 131

triage, 131

home isolation, 129

hospital admission, 121

hospital discharge, 125, 128

masks, 131

for multidrug-resistant tuberculosis patients, 126, 129

outpatient management, 122, 128

in pregnancy and post-partum, 130

respirators, 131, 133

returning to work, school or other congregate settings, 127, 129

sputum induction, 132

Infection rate, 154

Infectious period, 154, 155, 161 – see also *Contact evaluation*

Information for people living with tuberculosis patients, 245

Injectable anti-tuberculosis medications – see also *Amikacin, Capreomycin, Kanamycin, and Streptomycin*

adverse reactions to, 105, 111, 208, 210

breast feeding and, 211

central nervous system penetration of, 74, 211

dose and frequency of, 61, 85, 208, 210

drug interactions, 216

indications for, 83, 85, 86

in liver disease, 62, 211

monitoring, 209, 210, 215

in pregnancy, 57, 58, 211

in renal failure, 61, 211

Instructions for patients with potentially infectious tuberculosis, 244

Intensive phase of tuberculosis treatment, 43, 45, 58, 103

antiretroviral therapy during, 52

in children, 59, 60

daily treatment during, 13, 52, 53, 56

getting sputum culture at the end of, 12, 102, 103

intermittent therapy during, 44, 45

interrupted treatment during, 65, 66

using rifapentine at the end of, 12, 46, 47

Interferon-gamma for tuberculosis treatment, 91

Intermittent therapy and regimens, 44, 45

adherence, 101, 142, 143

adverse reactions, 111

directly observed therapy (DOT) and, 44, 104, 195

- for HIV-infected patients, 13, 53
- for isoniazid intolerant patients with tuberculosis disease, 87
- with rifamycins, 53, 54
- with rifapentine, 12, 46, 47
- in treatment of isoniazid (non-multi-drug resistant) tuberculosis, 87
- in treatment of latent tuberculosis infection, 195, 196
- in treatment of multidrug-resistant tuberculosis, 83, 87
- in treatment of tuberculosis disease, 44, 45, 53, 208, 210

International Classification of tuberculosis, 115, inside back cover

International Standards for tuberculosis Care, 235

Interrupted treatment, 65, 66

Isolation – see *Airborne infection isolation, Infection control*

Isolation of infectious non-adherent patients, 148 – see also *Regulatory Interventions*

Isoniazid

- adverse reactions to, 105, 110, 196, 208
- with Bacille Calmette-Guérin, 38
- breast feeding and, 58, 211
- central nervous system penetration of, 74, 211
- in children, 59, 196, 198
- dose and frequency of, 45, 196, 208
- drug interactions, 208, 217, 219, 223
- high-dose intermittent treatment, 91
- indications for, 45, 52, 53, 545, 186, 195, 196
- intermittent treatment, 44, 45, 196
- in liver disease, 61, 107, 191, 204, 211
- for latent tuberculosis infection treatment, 191, 195, 196
- retreatment candidates, 202
- monitoring, 208, 214
- in neonates, 38
- in pregnancy, 57, 104, 194, 200, 211
- in renal failure, 60, 211
- resistance (non-multi-drug resistant), 87
 - in Bacille Calmette-Guérin strains, 78
 - contacts to, 195, 196
 - fluoroquinolones for, 86
 - post-treatment evaluation, 95, 115, 116
 - pregnancy, 14, 86, 87
 - treatment of, 53, 86, 87
- with rifapentine, 12, 46
- treatment interruptions, 203
- for treatment of Class IV, 201, 202
- after treatment of tuberculosis disease, 117

Itching – see *Dermatitis*

Jaundice – see *Hepatitis*

Joint manifestations, 105, 111, 208, 210

Kanamycin – see *Aminoglycosides, Injectable anti-tuberculosis medications*

- adverse reactions to, 105, 111, 112, 210
- breast feeding and, 211
- central nervous system penetration of, 74, 211
- cross resistance to amikacin, 83, 91
- dose and frequency of, 61, 85, 210
- drug interactions, 216
- indications for, 83, 85, 86
- in liver disease, 62, 109, 211
- monitoring, 84, 208, 210, 215
- in neonates, 38
- in pregnancy, 58, 211
- in renal failure, 61, 211
- resistance, 90

Laboratory tests, 36, 103, 104, 190, 208, 210

Lactic acidosis, 94

Late complications of treated pulmonary tuberculosis, 212

Latent tuberculosis infection

- chest X-ray to rule out tuberculosis disease, 189, 190
- progression to active disease, 20, 192
- testing, 173
 - blood based tests, 183 see *QuantiFERON® TB Gold*
 - candidates for, 173, 174
 - targeted, 15
 - tuberculin skin test, 173, 182, 183
- treatment, 189
 - and Bacille Calmette-Guérin vaccination, 38, 227
 - candidates for, 192
 - in the case management flow chart, 140
 - case management of, 202
 - for children and infants, 122, 164, 193, 196, 197
 - for Class IV (old, healed tuberculosis), 13, 200
 - completion of, 205
 - for contacts, 153, 161, 162, 164, 169
 - infant and children, 164
 - return to supervision, 169, 193
 - with prior positive test for tuberculosis infection, 202
 - contraindications to isoniazid, 195
 - contraindications to rifampin, 198
 - directly observed therapy (DOT) for, 195, 203
 - dosages for, 196, 197
 - duration of, 196, 197
 - ensuring adherence, 203
 - follow-up after completion, 205
 - fluoroquinolones in, 92
 - hepatotoxicity and, 190, 191, 196, 197, 204
 - for HIV-infected patients, 162, 195, 196, 197
 - for immigrants, 232

- laboratory tests for patients considered for treatment, 190, 191
- liver function tests, 190, 191, 196, 197, 203, 204
- managing interruptions, 203
- medical history and physical examination for, 189, 194
- monthly monitoring, 196, 197, 202, 204
- with *Mycobacterium avium intracellulare*, 67
- for neonates, 38
- for persons exposed to multidrug-resistant tuberculosis, 92, 198, 199, 200, 201
- for pregnant women, 130, 176, 193, 194, 196, 200
- pretreatment evaluation and counseling, 191
- protease inhibitors and, 195, 196, 197
- pyridoxine (vitamin B6) and, 62, 196, 200
- repeat course of treatment, 189, 193, 202, 205
- regimens
 - alternative, 195
 - isoniazid, 195, 196
 - rifabutin, 195, 197
 - rifampin, 195, 196
 - rifampin and pyrazinamide, 15, 198
 - short course, 195
 - standard, 195
 - window period treatment, 38, 123, 155, 193

Lead shields, 27, 130, 190, 193

Length of treatment

- for children, regardless of culture results, 60
- for culture negative, pulmonary patients, 57, 58
- for culture positive, pulmonary patients, 43, 45, 57
- for extrapulmonary tuberculosis, 71, 72, 79
- for HIV-infected patients, 52, 53, 54
- for latent tuberculosis infection regimens, 195, 196, 197
- for multidrug-resistant tuberculosis infected contacts, 200
- for multidrug-resistant tuberculosis regimens, 86
- for pregnant women, 57, 58
- with rifapentine, 48
- for smear-negative, culture-negative patients, 13

Levofloxacin – see also *Fluoroquinolones*

- adverse reactions to, 13, 85, 92, 105, 210
- breast feeding and, 211
- central nervous system penetration of, 211
- in children, 85, 92, 210
- dose and frequency of, 86, 210
- drug interactions, 217
- indications for, 13, 85, 86, 91
- in liver disease, 62, 211
- monitoring, 93, 210
- in pregnancy, 85, 211
- in renal disease, 61, 211
- for treatment of drug-resistant tuberculosis, 85, 86, 91

for treatment of multidrug-resistant tuberculosis contacts, 201

Linezolid, 94

adverse reactions, 94, 105, 111, 112

drug interactions, 220, 221

indications for, 86, 94

monitoring, 94

pyridoxine for, 94

Liver disease – see *Hepatitis*

Liver function tests

before starting latent tuberculosis infection treatment, 190, 191, 194, 196, 197, 199

before starting tuberculosis treatment, 36, 48, 103, 104

during latent tuberculosis infection treatment, 196, 197, 203, 204

during tuberculosis treatment, 103, 104, 107, 109, 194

patterns of elevation, 108

Living with patients with tuberculosis, 245

Liver sparing regimens, 61 – see also *Hepatitis*

LTBI – see Latent tuberculosis infection

Lymphatic tuberculosis, 72

MAC – see *Mycobacterium avium-intracellulare*

Magnesium, 62, 111, 208, 210

Magnetic resonance imaging (MRI) for tuberculosis diagnosis, 72, 75

MAI – see *Mycobacterium avium-intracellulare*

Mantoux test, 15, 173, 178, 192 – see *Tuberculin skin test*

Masks, 131, 132

MDRTB – see Multi-drug-resistant tuberculosis

Meals and anti-tuberculosis medications, 62

Measles, Mumps, and Rubella (MMR) vaccination, 179

Medical evaluation

before latent tuberculosis infection treatment, 162, 163, 189, 191, 194

before tuberculosis treatment, 26

on the case management flow chart, 140

for children, 37

for extrapulmonary tuberculosis, 72

monthly examination during latent tuberculosis infection treatment, 196, 197, 202, 204

monthly examination during tuberculosis treatment, 101, 103, 208, 210

Medical risk factors for the development of tuberculosis, 173, 174

in children, 177

MEMS cap monitoring – see *Electronic cap monitoring*

Meningeal tuberculosis – see *Central nervous system tuberculosis*

Meningitis, tuberculosis – see *Central nervous system tuberculosis*

Methadone

adverse reactions for patients on, 196, 197, 208

directly observed therapy (DOT) programs and, 145

drug interactions, 218, 224

Microbiologic evaluation, 27

Miliary tuberculosis – see *Disseminated tuberculosis*

in children, 37, 60, 71, 75, 227

pattern on chest x-ray, 72, 75, 122

MIRU – see *Mycobacterial interspersed repetitive units*

Mission Statement of the Bureau of Tuberculosis Control, 20

Molecular genotyping – see *Genotyping*

Monitoring

for HIV-infected patients, 51, 53, 56, 103, 104, 203

for liver disease, 61

monthly nurse assessment, 103, 105

monthly physician assessment, 101, 103

with rifapentine, 48

therapeutic drug monitoring, 214

after treatment completion, 115, 116

during treatment of drug-resistant tuberculosis, 84, 95, 101, 103, 208, 210

during treatment of latent tuberculosis infection, 189, 196, 197, 202

during treatment of tuberculosis disease, 101, 103, 208, 210

Moxifloxacin – see also *Fluoroquinolones*

adverse reactions to, 13, 85, 92, 105, 210

breast feeding and, 211

central nervous system penetration of, 211

in children, 85, 92, 210

dose and frequency of, 210

drug interactions, 217, 224

indications for, 13, 85, 86, 91, 92, 210

in liver disease, 61, 211

monitoring, 93, 210

in pregnancy, 85, 211

in renal failure, 61, 211

for treatment of drug-resistant tuberculosis, 85, 86, 91

for treatment of multidrug-resistant tuberculosis contacts, 201

MTD® Test – see *Nucleic acid amplification tests*

Multidrug-resistant tuberculosis (MDRTB), 83

adherence to treatment, 144

in the central nervous system, 75

contacts of patients with, 198, 199, 200, 201, 205

definition, 83

discharge from the hospital for patients with, 121, 126, 129

epidemiology, 16

gastric aspirates in children with, 28

home isolation for patients with, 129

monitoring, 84, 95, 102, 208, 210

post-treatment evaluation for patients with, 14, 95, 115, 116

regimens, 58, 85, 86

return to work or school for patients with, 129

risk factors for, 26

surgery for, 88, 89, 90, 91, 95

treatment failure, 83

treatment, 85, 86 – see *Individual drugs used*

- for children, 38, 84, 85, 86, 208, 210
- with clofazimine, 95
- with directly observed therapy, 64, 83
- extension of, 83, 88, 89, 90, 91
- with fluoroquinolones, 83, 85, 91
- with linezolid, 94
- for pregnant women, 58, 84
- principles, 83, 85

Mycobacterial interspersed repetitive units (MIRU), 34

Mycobacterium avium complex – see *Mycobacterium avium-intracellulare*

Mycobacterium avium-intracellulare

- treatment of coexistent tuberculosis and, 67

***Mycobacterium bovis*, 32, 78, 84 227, 229**

Mycobacterium other than tuberculosis (MOTT) – see *Nontuberculous mycobacteria*

National Jewish Medical and Research Center, 33, 215

Nausea, 48, 92, 94, 95, 105, 107, 110, 196, 197, 203, 204, 208, 210 – see *Hepatitis, Gastritis*

Negative tuberculin skin test reaction – see *Tuberculin skin test*

- anergy, 182

- boosting, 182

- classification of, 179, 180

- in contact investigations, 162, 163, 164

- false-negative, 181

- follow-up for (among contacts), 162

Neonatal tuberculosis – see *Congenital tuberculosis*

Neurologic and psychiatric manifestations, 105, 210

NNRTIs – see *Non-nucleoside reverse transcriptase inhibitors*

NRTIs – see *Nucleoside/Nucleotide reverse transcriptase inhibitors*

Non-adherence – see *Adherence*

Non-counted case, 78, 154

Non-tuberculous mycobacteria, 95, 181, 183

Non-nucleoside reverse transcriptase inhibitors, 14, 50, 51, 54, 55

- with ethionamide, 217

- with rifabutin, 49, 50, 51, 54, 55, 195, 197, 208, 221

- with rifampin, 49, 50, 54, 55, 195, 196, 208, 221

- with rifapentine, 48

Nucleic acid amplification tests, 30

- airborne infection isolation and, 125

- contact investigation, 155, 156

- for extrapulmonary specimens, 31

- in meningeal tuberculosis, 74

- reporting, 229

Nucleoside/Nucleotide reverse transcriptase inhibitors, 50, 51

Number of doses for completing tuberculosis treatment, 45, 54 – see also *Dosages for tuberculosis treatment*

Numbness – see *Peripheral neuropathy*

Ofloxacin – see *Fluoroquinolones*

Old, healed tuberculosis – see *Class IV*
Optic neuropathy – see *Visual manifestations*
Oxazolidinones – see *Linezolid*

Para-aminosalicylic acid

adverse reactions to, 104, 105, 110, 210
breast feeding and, 211
central nervous system penetration of, 211
dose and frequency of, 210
drug interactions, 219, 221
indications for, 89, 90, 91
in liver disease, 110, 211
monitoring, 210
in pregnancy, 211
in renal failure, 60, 211
therapeutic drug monitoring for, 215
thyroid function testing and, 104, 210
for the treatment of drug-resistant tuberculosis, 89, 90

Paradoxical reactions

HIV-related – see *Immune reconstitution inflammatory syndrome (IRIS)*
Non-HIV-related, 113

Particulate respirators – see *Respirators*

PAS – see *Para-aminosalicylic acid*

Pathogenesis of tuberculosis, 25

Patients' Charter for Tuberculosis Care, 237, 238

Patients' Rights, 238
Patients' Responsibilities, 239

PCR (polymerase chain reaction) test – see *Nucleic acid amplification tests, Mycobacterial interspersed repetitive units (MIRU), Spoligotyping*

Pediatric tuberculosis – see *Children with tuberculosis*

Pericardial tuberculosis, 72, 73, 79, 121, 123

Peripheral neuropathy, 62, 94, 105, 110, 196, 208, 217, 220

Peritoneal tuberculosis, 72, 77, 79

Photosensitivity/Phototoxicity, 92, 106, 210

Physical examination – see *Medical evaluation*

Pleural tuberculosis, 27, 29, 71, 72, 79, 158

Polymerase chain reaction (PCR) – see *Nucleic acid amplification tests, Mycobacterial interspersed repetitive units, Spoligotyping*

Positive tuberculin skin test reaction, 154 – see *Tuberculin skin test*
classification of, 179, 180

Post-treatment evaluation after tuberculosis treatment, 115
frequency of, 116

PPD test – see *Tuberculin skin test*

Pregnancy

adherence to tuberculosis treatment, 142
Bacille Calmette-Guérin vaccination and, 228
chest X-ray, 27, 190 – see *Lead shields*
congenital and neonatal tuberculosis and, 38, 39

- infection control, 130
- latent tuberculosis infection treatment, 193, 194, 195, 196, 198, 200
 - evaluation of tuberculosis risk, 191, 194
 - monitoring, 203, 204
- nevirapine and, 51
- pyrazinamide use in, 13, 86, 87
- pyridoxine (vitamin B6) and, 62, 209
- safety of tuberculosis drugs, 211
- treatment of tuberculosis disease, 13, 14, 56, 86, 87
 - for isoniazid resistant or intolerant patients, 13, 86, 87
 - for HIV-infected women, 51, 53
 - for multidrug-resistant tuberculosis, 58, 84, 86
- tests for tuberculosis infection, 130, 176

Prophylaxis – see also *Latent tuberculosis infection treatment*

- after tuberculosis treatment, 117
- window period, 38, 122, 123, 126, 128, 164
- with cotrimoxazole, 236
- for cutaneous tuberculosis, 78
- with isoniazid, 78
- for *Mycobacterium avium intracellulare*, 67

Protease inhibitors, 14, 48, 49

- use with ethionamide, 217
- use with rifabutin, 50, 54, 55, 195, 197, 208, 221
- use with rifampin, 50, 54, 55, 195, 196, 208, 221
- use with rifapentine, 48

Psychiatric manifestations, 105, 210

Public Health Laboratories, 33, 214

Pyrazinamide

- adverse reactions to, 101, 105, 106, 107, 110, 208
- breast feeding and, 211
- central nervous system penetration of, 74, 211
- in children, 59, 74
- discontinuation of, 43, 44, 45, 103
- dose and frequency of, 208
- drug interactions, 219, 221, 225
- drug susceptibility testing for, 32, 83
- indications for, 43, 44, 45, 86, 87, 88, 89, 91
- length of tuberculosis treatment and treatment completion, 43, 44, 45, 64
- in liver disease, 61, 107, 108, 109, 211
- for latent tuberculosis infection treatment, 15, 198
 - for Class IV, 201
 - for multidrug-resistant tuberculosis contacts, 201
 - with rifampin, 198
- Mycobacterium bovis* and, 78, 84
- monitoring, 103, 209
- in neonates, 38
- in pregnancy, 13, 57, 58, 211
- in renal failure, 61, 111, 211

resistance, 89, 90

restarting tuberculosis meds with, 109

Pyridoxine (vitamin B6), 57, 62, 91, 94, 103, 110, 196, 201, 209, 210, 221

with cycloserine, 62, 201, 210

drug interactions, 221

with linezolid, 94

for treatment of multidrug-resistant tuberculosis contacts, 201

QT interval prolongation, 92, 93, 210, 217

QuantIFERON® TB Gold, 183, 184 – see *Blood-based tests for tuberculosis infection*

advantages of, 183

in Bacille Calmette-Guérin-vaccinated persons, 183, 184

classification of the reaction, 184

compared to TST, 184

costs and benefits of, 184

eligibility for, 184

indications for health care workers, 184

interpretation of, 184

limitations, 184

two-step testing, 183, 184

Quinolones – see *Fluoroquinolones*

Rapid diagnostic tests – see *Nucleic acid amplification tests*

Rash – see *Dermatitis*

Rates of

death in tuberculosis meningitis, 75

relapse in extrapulmonary tuberculosis, 71

relapse in culture positive pulmonary tuberculosis, 46

sputum culture sensitivity and specificity, 31

tuberculosis in New York City, 16

Reclassification of tuberculosis suspects, 114

Re-exposure to tuberculosis, 117, 163, 164, 193

Refugees – see *Immigrants*

Regimens for latent tuberculosis infection treatment, 195, 196, 197 – see *Latent tuberculosis infection*

Regimens for tuberculosis treatment, 43, 45

for children, 59, 60

for drug-resistant patients, 86

for HIV-infected patients on antiretrovirals, 52, 54

intermittent, 44, 45

for patients with chronic renal failure, 60

for patients with liver disease, 61

for pregnant women, 56

with rifapentine, 46, 47

Regulatory interventions, 145

Commissioner's Orders, 145, 147

Health Code sections for, 147

infectious or potentially infectious patients who want to leave hospital, 148

referral for, 145

Relapse, 27, 35, 43, 44, 46, 52, 53, 56, 64, 71, 87, 102, 115, 154, 164, 214

Renal failure, 60, 83, 92, 160, 180, 181, 196, 211

Renal manifestations, 105, 111, 208, 210

Renal tuberculosis, 71, 76 – see *Genitourinary tuberculosis*

Repeat course of treatment for latent tuberculosis infection, 189, 193, 202, 205

Reporting requirements, 16, 229

Respirators, 131, 133

Restricted fragment length polymorphism (RFLP) – see *Genotyping*

Restarting anti-tuberculosis medications

after audiovestibular manifestations, 113

after dermatitis, 106

after gastritis, 110

after hematologic abnormalities, 112

after hepatitis, 107, 109

after interruptions, 65, 66, 203

for women who become pregnant while on latent tuberculosis infection treatment, 200

Return to supervision (RTS)

for latent tuberculosis infection, 169

for tuberculosis, 143

Return to work, school or congregate setting, 127, 129

for multidrug-resistant tuberculosis patients, 126, 129

for sputum acid-fast bacilli smear-negative patients, 127

for sputum acid-fast bacilli smear-positive patients, 127

Reversion of acid-fast bacilli smear or culture, 154

Rifabutin

adverse reactions to, 50, 56, 105, 111, 112, 208, 210

with antiretrovirals, 49, 52, 54, 55, 195, 197

breast feeding and, 211

central nervous system penetration of, 211

dose and frequency of, 53, 54, 55, 197, 208

drug interactions, 49, 54, 55, 221

for HIV-infected persons, 14, 49, 54, 55, 195, 197

indications for, 14, 45, 54, 86, 195, 197

intermittent treatment, 53, 54

in liver disease, 61, 108, 109, 211

for latent tuberculosis infection treatment, 195, 197

with MAI, 67

monitoring, 209

in pregnancy, 211

in renal failure, 211

resistance, 90, 91

with rifampin resistance, 85, 88, 89, 90

Rifamate®, 43, 57, 201, 208

Rifater®, 208

Rifampin

adverse reactions to, 105, 106, 107, 110, 111, 112, 196, 208, 210

and antiretrovirals, 49, 50, 51, 54, 55

- breast feeding and, 211
- central nervous system penetration of, 74, 75, 211
- in children, 59, 195, 196, 208
- dose and frequency of, 43, 45, 103, 195, 196, 208
- drug desensitization, 113
- drug interactions, 49, 50, 51, 54, 55, 208, 220, 221
- indications for, 14, 45, 86, 195, 196
- intermittent treatment, 44, 45, 53, 196
- in liver disease, 61, 107, 109, 211
- for latent tuberculosis infection treatment, 164, 195, 196
 - contraindications of treating with rifampin, 196
 - with pyrazinamide, 15, 198
- with *Mycobacterium avium intracellulare*, 67
- monitoring, 196, 209, 214
- in neonates, 38
- in pregnancy, 57, 130, 211
- in renal failure, 60, 111, 211
- resistance
 - acquired, 46, 53, 117
 - contacts to patients with, 198
 - development of, 117
 - HIV-infection and, 53, 87, 117
 - monitoring, 102
 - post-treatment evaluation, 95, 115, 116
 - risk factors for, 46, 53
 - treatment of, 83, 86, 87, 88, 89, 90
- restarting, 106, 108, 109, 110
- rifabutin susceptibility and, 85
- for treatment of Class IV, 200
- for treatment of drug-resistant tuberculosis, 86

Rifamycins – see *Rifabutin*, *Rifampin* and *Rifapentine*

Rifapentine

- adverse reactions to, 48, 105, 111, 208
- breast feeding, 48, 211
- central nervous system penetration of, 211
- in children, 47, 48, 60
- directly observed therapy (DOT) and, 44, 46, 63
- dose and frequency of, 44, 45, 47, 48
- drug interactions, 48, 49, 209, 221
- in HIV-infected patients, 13, 46, 47
- indications for, 12, 13, 44, 45, 46, 47
- length of treatment, 13, 45, 47, 48, 60, 103
- in liver failure, 211
- monitoring, 48, 101, 103, 209
- in pregnancy, 13, 46, 47, 48, 211
- in renal failure, 211

Risk assessment of tuberculosis in children, 176, 177

Risk factors for developing tuberculosis disease, 15, 155, 174, 180, 198

Screening for tuberculosis – see *Tuberculin skin testing, Blood-based tests for tuberculosis infection*

Selective serotonin reuptake inhibitors (SSRIs), 95

Separation of mother and child, 38, 57, 130

Serotonin syndrome, 95

Short-course latent tuberculosis infection treatment, 195, 200

Short-term treatment for Class IV, 13, 201

Skeletal tuberculosis, 76, 79

Skin test – see *Tuberculin skin test*

Source case, 154

Source case investigation, 26, 153, 154, 157, 162, 163, 167

Spoligotyping, 34, 35, 36

Sputum induction, 28, 102, 132, 198

clearance times for chest center booths/rooms, 134

description of procedure, 132

Sputum smears – see *Acid-fast bacilli smears*

Strain W, 83, 86, 90

Streptomycin – see *Aminoglycosides, Injectable anti-tuberculosis medications*

adverse reactions to, 105, 111, 112, 208

breast feeding and, 211

central nervous system penetration of, 74, 211

in children, 59, 84

with tuberculosis meningitis, 59, 74

dose and frequency of, 61, 85, 208

drug interactions, 216, 217

indications for, 58, 83, 85, 86, 87, 88, 89, 90

in liver disease, 62, 211

monitoring, 84, 209, 215

in pregnancy, 57, 58, 211

pyrazinamide and, 57

in renal failure, 61, 211

resistance, 83, 86, 87, 88, 89, 90, 91

rifapentine use and, 47

Surgery for tuberculosis

genitourinary, 76

pulmonary, 88, 89, 90, 91, 95, 96

Surveillance, 15

of false-positive cultures, 35

Surveillance for tuberculosis by Health Systems Examination, 234

Susceptibility testing – see *Drug susceptibility testing*

Suspected tuberculosis, 20, 36, 229 – see *Class V (High) versus (Low)*

Targeted testing, 15, 20, 173, 176, 177

Tendinopathy/tendonitis, 92, 105, 210

Tests for tuberculosis infection (TTBI), 173, 183

blood-based tests – see *QuantiFERON® TB Gold*

Mantoux test – see *Tuberculin skin test*

skin test – see *Tuberculin skin test*

Therapeutic drug monitoring, 61, 214

Three times a week therapy, 43 – see *Intermittent therapy*
for children, 59

on directly observed therapy, 63

for HIV-infected persons, 13, 50, 51, 53, 54, 55, 56

for injectable anti-tuberculosis medications, 61, 85, 87, 88

renal failure and, 60, 61

for treatment of tuberculosis, 13, 44, 45, 87, 208

Thyroid function tests, 104, 105, 210

Tinnitus – see *Audiovestibular manifestations*

Torsades de pointes, 217 – see *Cardiotoxicity, Ventricular tachyarrhythmia, QT prolongation*

Transmission, 25

assessing risk of, 161

contact evaluation and, 153, 165

determination of, 154

epidemiological assessment of, 155

outpatient treatment and, 14, 121

Treatment failure, 27, 67, 75, 96, 102, 154, 236

in multidrug-resistant tuberculosis patients, 83, 84

Treatment – see *Dosages, Drug-resistant tuberculosis, Extrapulmonary tuberculosis, Latent tuberculosis Infection, Length of Treatment, Multidrug Resistant tuberculosis, Medical Evaluation, and Monitoring*

Treatment of tuberculosis disease

antiretroviral therapy and, 49, 54, 55

antituberculosis drugs and meals, 62

chest x-ray in initial evaluation for, 27, 103

in children, 59

completion of, 64

continuation phase, 43

prolonging treatment during, 12, 13, 43, 45, 47, 48

directly observed therapy (DOT), 12, 44, 45, 47, 63, 83

dosages for, 43, 47, 208, 210

in extrapulmonary tuberculosis – see individual sites

failure of, 67, 83, 84

in HIV-infected patients, 49, 52, 54, 55 – see *HIV-infection*

intensive phase, 43

intermittent regimens for, 44, 45, 47

interrupted, 65, 66

length of treatment, 43, 48, 53, 57, 60, 66

length of treatment for drug-resistant tuberculosis, 86, 87, 88, 89, 90, 91 – see multidrug-resistant tuberculosis

liver function tests, 36, 103, 104, 209

with *Mycobacterium avium intracellulare*, 67

medical evaluation (initial) for, 26, 36, 103, 209

monthly monitoring, 85, 101, 103, 208, 210

number of doses needed for treatment, 45, 64

in patients with liver disease, 61, 211

in patients with negative nucleic acid amplification tests, 30
in patients with renal failure, 60, 211
post-treatment evaluation for, 115, 116
in pregnant women, 56
pyridoxine (vitamin B6) and, 62, 209 – see *Pyridoxine*
rifapentine for, 12, 45, 46, 47, 208
sputum specimens during, 27, 101, 103
standard regimens for, 43

Tuberculin skin test (TST), 15, 173, 178, 192
administration of, 178
anergy and, 182
in Bacille Calmette-Guérin-vaccinated persons, 174, 179, 182
booster phenomenon and, 182
candidates for testing, 173, 174, 176, 177
classification of the reaction, 180, 191
conversion of, 154
determination of positive, 180
false-negative results of, 181
false-positive results of, 181
interpretation of, 179
Mantoux vs. Tine, 178
measles, mumps, rubella (MMR) vaccine and, 179
in pregnant women, 130, 176
QuantiFERON® TB Gold and, 183
reading the reaction of, 179
two-step testing, 182, 183

Tuberculoma, 75

Tumor necrosis factor alpha (TNF-) blockers/antagonists, 122, 173, 174, 176, 180, 192

Twice weekly therapy – see *Two times a week therapy, Biweekly therapy*

Two times a week therapy – see also *Intermittent therapy, Biweekly therapy, Twice weekly therapy*

continuation of lapsed treatment, 65
on directly observed therapy (DOT), 63
for HIV-infected persons, 13, 51, 53, 54, 55, 56
for injectable anti-tuberculosis medications, 85, 88
for pyridoxine, 62
renal failure and, 61
for treatment of latent tuberculosis infection, 195, 196, 197
for treatment of tuberculosis, 44, 45, 208

Two-step tuberculin skin testing, 182, 192

Unexposed, 155

Universal reporting form (URF), 16, 123, 128, 230

Ventricular tachyarrhythmia, 92

Vertigo, 105, 113 – see *Audiovestibular manifestations*

Vision loss – see *Visual manifestations*

Visual acuity, 27, 59, 61, 103, 105, 208, 209

Visual manifestations 61, 94, 105, 112, 208, 209
in children, 14, 27, 59

Vitamin B6 – see *Pyridoxine*

Vomiting, 48, 92, 94, 95, 105, 107, 110, 196, 197, 203, 204, 208, 210, 220

W strain – see *Strain W*

Window period, 162, 163, 164, 166, 176

Window period treatment (prophylaxis), 38, 122, 123, 126, 128, 155, 193

World Health Organization (WHO), 57, 168, 211

XDRTB – see *Extreme drug-resistant tuberculosis*

ERRATA AND ADDITIONS
TUBERCULOSIS
CLINICAL POLICIES AND PROCEDURES, 4TH EDITION MARCH 2008

Section II, Initial Evaluation of Suspected Tuberculosis

Page 33, Table II-2, replace superscript *c* in MGIT column with 3

Section IV, Evaluation and Treatment of Extrapulmonary Tuberculosis

Page 72, addition in left column, end of first full paragraph. *In several forms of TB, corticosteroids have been shown to be useful (see Table IV-2).*

Page 73, replace *(Meningeal), Tuberculoma* with *Central Nervous System Tuberculosis*

Section VII, Infection Control

Page 127, left column, paragraph 9, replace *smear* with *culture*

Page 129, left column, third bullet point, replace *Hospitals* with *Patient care areas*

Section IX, Contact Evaluation and Public Health Management

Page 156, Table IX-1, upper half of table, under second column (Nucleic Acid Amplification Result move *Or/Not done* ” from under “Negative for M.tb” to under “Positive for M.tb”

Table IX-1, upper half of table, under last column entitled “complete,” in the first box, *add if verified* so that the cell reads, *Yes, if verified.*

Page 167, left column, under Airline Exposures, second paragraph, change *BTBC* to *CDC/DGM* in sixth and eighth lines.

Section XI, Latent TB Infection (LTBI): Evaluation, Treatment, Monitoring and Follow-up

Page. 192, right column, after the first three bullets add, *For guidelines on when to give a repeat course of treatment for LTBI in contacts that have already completed such treatment, see pages 163 and 193.*

Page 199, right column, first bullet, second line, change *older* to *younger*

Replace *flouroquinolones* with *fluoroquinolones* on:

Page 92, left column, third paragraph

Page 210 in the second footnote (twice)

Replace *para-aminosalicylic* with *para-aminosalicylic* on:

Page 210 (2 times)

Page 211

Page 215, first bullet



*Michael R. Bloomberg,
Mayor*

**Department of
Health & Mental
Hygiene**

*Thomas R. Frieden, M.D., M.P.H.
Commissioner*